文献速递骨软组织肉瘤与黑色素瘤

转移性葡萄膜黑色素瘤的生物标志物驱动治疗:一项前瞻性精准肿瘤学可行性研究

Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study.
PubMed 文献 · Eur J Cancer · 2022-05-12

该前瞻性研究评估了在常规临床实践中对转移性葡萄膜黑色素瘤患者实施精准肿瘤学策略的可行性。45例患者中39例(87%)获得分子分析结果,40例(89%)获得治疗推荐,27例(60%)接受至少一种匹配治疗。一线匹配治疗的最佳反应为1例部分缓解、2例混合反应、12例疾病稳定,临床获益率56%。

要点

  • 45例患者中39例(87%)获得分子分析结果,40例(89%)获得治疗推荐,27例(60%)接受至少一种匹配治疗。
  • 一线匹配治疗最佳反应:1例部分缓解(基于肿瘤突变负荷的纳武利尤单抗)、2例混合反应、12例疾病稳定,临床获益率56%。
  • 匹配治疗人群的中位无进展生存期为3.3个月,中位总生存期为13.9个月。

核心结论

  • 精准肿瘤学方法对转移性葡萄膜黑色素瘤患者可行,60%的患者接受了与所识别分子异常相匹配的治疗。
  • 免疫检查点抑制剂后的临床获益凸显了肿瘤突变负荷检测的价值。

研究设计与样本

  • 前瞻性精准肿瘤学可行性研究(Treat20 Plus研究),在常规临床实践中评估精准肿瘤学策略的可行性。
  • 对新鲜活检组织进行高通量基因组分析(全基因组、全外显子组和RNA测序)。
  • 多学科分子与免疫肿瘤委员会(MiTB)根据识别的分子异常、患者情况、药物和临床试验可及性做出个体化治疗推荐。
  • 治疗选择由主治医师自行决定。
  • 主要终点为精准肿瘤学临床项目的可行性。

主要发现

  • 45例患者中39例(87%)可获得分子分析结果。
  • MiTB为45例患者中的40例(89%)提供了治疗推荐,其中27例(60%)接受了至少一种匹配治疗。
  • 一线匹配治疗包括MEK抑制剂(n=15)、MET抑制剂(n=10)、索拉非尼(n=1)和纳武利尤单抗(n=1)。
  • 一线匹配治疗的最佳反应为1例部分缓解(基于肿瘤突变负荷的纳武利尤单抗)、2例混合反应和12例疾病稳定,临床获益率为56%。
  • 匹配治疗人群的中位无进展生存期为3.3个月,中位总生存期为13.9个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted therapies for metastatic uveal melanoma have shown limited benefit in biomarker-unselected populations. The Treat20 Plus study prospectively evaluated the feasibility of a precision oncology strategy in routine clinical practice. PATIENTS AND METHODS: Fresh biopsies were analyzed by high-throughput genomics (whole-genome, whole-exome, and RNA sequencing). A multidisciplinary molecular and immunologic tumor board (MiTB) made individualized treatment recommendations based on identified molecular aberrations, patient situation, drug, and clinical trial availability. Therapy selection was at the discretion of the treating physician. The primary endpoint was the feasibility of the precision oncology clinical program. RESULTS: Molecular analyses were available for 39/45 patients (87%). The MiTB provided treatment recommendations for 40/45 patients (89%), of whom 27/45 (60%) received ≥1 matched therapy. First-line matched therapies included MEK inhibitors (n = 15), MET inhibitors (n = 10), sorafenib (n = 1), and nivolumab (n = 1). The best response to first-line matched therapy was partial response in one patient (nivolumab based on tumor mutational burden), mixed response in two patients, and stable disease in 12 patients for a clinical benefit of 56%. The matched therapy population had a median progression-free survival and overall survival of 3.3 and 13.9 months, respectively. The growth modulation index with matched therapy was >1.33 in 6/17 patients (35%) with prior systemic therapy, suggesting clinical benefit. CONCLUSIONS: A precision oncology approach was feasible for patients with metastatic uveal melanoma, with 60% receiving a therapy matched to identify molecular aberrations. The clinical benefit after checkpoint inhibitors highlights the value of tumor mutational burden testing.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Leyvraz S, Konietschke F, Peuker C, et al. Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study. Eur J Cancer. 2022. PMID: 35569281. doi:10.1016/j.ejca.2022.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。